Kuehn Law, PLLC is investigating whether certain officers and directors of Arcus Biosciences, Inc. breached their fiduciary duties through potential self-dealing. The investigation could lead to shareholder damages and corporate governance reforms. Long-term shareholders are encouraged to contact the law firm to protect their rights, as there may be limited time to act. The firm offers free consultation and covers all case costs for investors.
Bank of America upgraded DraftKings stock to Buy from Neutral, citing reduced risks from prediction markets and a favorable risk-reward at current prices. DraftKings shares rose 5% following the upgrade, while competitors Flutter Entertainment and MG...
Vertiv has named Michael Resha as Executive Vice President of Manufacturing, Logistics, and Operational Excellence, succeeding Anders Karlborg who moves to a new role. Resha will lead global manufacturing and logistics efforts to scale operations and...
Bitmine increased its Ether (ETH) holdings by 15,112 coins last week, bringing its total to 6,016,414 ETH. This accumulation highlights Bitmine's ongoing investment in Ethereum, signaling confidence in the digital asset's future. The move may influen...
Cerrado Gold (CRDOF) has been upgraded to a Buy rating due to improved production at its Minera Don Nicolas (MDN) mine, which reached 15,415 gold equivalent ounces in Q2, supporting the annual target of 50,000 GEO. However, cost control remains a cha...
Rapid Dose Therapeutics announced it will issue common shares to settle $142,067.63 of accrued interest on its secured convertible notes by October 15, 2026. The notes, originally issued in 2023, bear 18% annual interest payable quarterly in shares a...
